Page 1

Q2 Key Figures April 1 - June 30 , 2021 CALLIDITAS THERAPEUTICS AB ( publ ) Interim Report January 1 - June 30 , 2021 Filing of Marketing Authorisation Application on accelerated basis with EMA No net sales were recognized for the three months ended June 30 , 2021 and 2020 , re spectively . Operating loss amounted to SEK 159.4 mil lion and SEK 66.6 million for the three months ended June 30 , 2021 and 2020 , re spectively . Loss before income tax amounted to SEK 165.2 million and SEK 61.3 million for the three months ended June 30 , 2021 and 2020 , respectively . Cash amounted to SEK 709.3 million and SEK 1,459.6 million as of June 30 , 2021 and 2020 , respectively . January 1 - June 30 , 2021 ● calliditas ● Loss per share before and after dilution amounted to SEK 3.20 and SEK 1.50 for the ● three months ended June 30 , 2021 and 2020 , respectively . THERAPEUTICS No net sales were recognized for the six month ended June 30 , 2021. Net sales amounted to SEK 0.5 million for the six months ended June 30 , 2020 . Operating loss amounted to SEK 310.2 mil lion and SEK 138.9 million for the six months ended June 30 , 2021 and 2020 , re spectively . Loss before income tax amounted to SEK 301.4 million and SEK 124.9 million for the six months ended June 30 , 2021 and 2020 , respectively . Loss per share before and after dilution amounted to SEK 5.71 and SEK 3.14 for the six months ended June 30 , 2021 and 2020 , respectively . Significant events during the period April 1 - June 30 , 2021 , in summary In April 2021 , Calliditas was granted accelerated assessment procedure by the European Medicine Agency's ( EMA ) Committee for Human Medicinal Products ( CHMP ) for Nefecon , reducing the maximum timeframe for review of the application for marketing authorization . If approved , Nefecon could be available to patients in Europe in first half of 2022 . In April 2021 , Calliditas announced that the FDA accepted the submission and granted Pri ority Review for the NDA for Nefecon . The FDA have set a Prescription Drug User Fee Act ( PDUFA ) goal date of September 15 , 2021. Subject to approval , this would enable commer cialisation of Nefecon in the US in Q4 , 2021 . Interim Report Q2 | January - June , 2021